{"gene":"PRKN","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":2008,"finding":"Parkin is selectively recruited from the cytosol to dysfunctional mitochondria with low membrane potential, where it mediates engulfment of mitochondria by autophagosomes and promotes selective elimination of impaired mitochondria (mitophagy).","method":"Live-cell imaging, mitochondrial membrane potential assays, autophagosome colocalization in mammalian cells","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — foundational discovery, highly cited (3295 citations), multiple orthogonal methods, replicated across many subsequent studies","pmids":["19029340"],"is_preprint":false},{"year":2010,"finding":"PINK1 accumulation on damaged mitochondria (regulated by voltage-dependent proteolysis that keeps PINK1 low on healthy mitochondria) is both necessary and sufficient for Parkin recruitment to mitochondria; disease-causing mutations in PINK1 and Parkin disrupt Parkin recruitment and Parkin-induced mitophagy at distinct steps, establishing PINK1 acts upstream of Parkin.","method":"Genetic epistasis in mammalian cells, dominant-negative and loss-of-function mutations, PINK1 overexpression/knockdown, mitophagy assays","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 2 — foundational epistasis and biochemical study with multiple orthogonal methods, 2377 citations, widely replicated","pmids":["20126261"],"is_preprint":false},{"year":2014,"finding":"PINK1 phosphorylates ubiquitin at Ser65 both in vitro and in cells; phosphorylated ubiquitin (phosphoUb) acts as an allosteric activator of Parkin E3 ligase activity by accelerating discharge of the UbcH7~ubiquitin thioester conjugate; PINK1-dependent phosphorylation of both Parkin and ubiquitin is sufficient for full activation of Parkin E3 activity.","method":"In vitro kinase assay, phosphopeptide mass spectrometry, in vitro ubiquitin discharge assay with recombinant proteins, phosphomimetic ubiquitin rescue experiments in cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis, replicated by multiple groups, 1199 citations","pmids":["24784582"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of Pediculus humanus Parkin in complex with Ser65-phosphorylated ubiquitin reveals the molecular basis for Parkin recruitment and activation: phosphoUb binds a conserved phosphate pocket in RING1 (involving AR-JP mutation residues), straightens a RING1 helix causing conformational changes that release the Ubl domain from the Parkin core, activating Parkin; phosphoUb-mediated Ubl release also enhances Ubl phosphorylation by PINK1, stabilizing an open active conformation.","method":"Crystal structure (X-ray crystallography), mutagenesis, biochemical binding assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation and mutagenesis of AR-JP disease mutations","pmids":["26161729"],"is_preprint":false},{"year":2018,"finding":"Full-length human Parkin undergoes large-scale domain rearrangement upon activation: phospho-Ubl rebinds to the Parkin core (UPD domain via a phosphate-binding pocket lined by AR-JP mutations) and releases the catalytic RING2 domain; a conserved linker region (ACT element) between Ubl and UPD mimics RING2 interactions to aid RING2 release; 1.8 Å crystal structure of phosphorylated human Parkin determined.","method":"Hydrogen-deuterium exchange mass spectrometry, 1.8 Å crystal structure of phosphorylated human Parkin, mutagenesis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure combined with HDX-MS and mutagenesis in a single rigorous study","pmids":["29995846"],"is_preprint":false},{"year":2018,"finding":"Crystal structure of phosphorylated Bactrocera dorsalis Parkin in complex with phosphorylated ubiquitin and an E2 ubiquitin-conjugating enzyme reveals that the key activating step is movement of the Ubl domain and release of the catalytic RING2 domain; HDX and NMR experiments with activation intermediates confirm large domain movements in mammalian Parkin activation.","method":"Crystal structure (X-ray crystallography), hydrogen/deuterium exchange, NMR, mutagenesis","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with orthogonal biophysical methods validating the activation mechanism","pmids":["29967542"],"is_preprint":false},{"year":2015,"finding":"Phosphorylated ubiquitin chain (not monomeric phosphoUb) is the genuine Parkin receptor on mitochondria: linear phosphomimetic tetra-ubiquitin(S65D) recruits Parkin to energized mitochondria in absence of PINK1; physical interaction between phosphomimetic Parkin and phosphorylated polyubiquitin chain detected by Co-IP from cells and by in vitro reconstitution with recombinant proteins.","method":"Cellular ubiquitin replacement system, Co-IP from cells, in vitro reconstitution with recombinant proteins, lysosomal phosphorylated polyubiquitin chain recruitment assay","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro reconstitution plus cellular rescue experiments with orthogonal approaches","pmids":["25847540"],"is_preprint":false},{"year":2015,"finding":"Phospho-ubiquitin binding to RING1 of Parkin (at His302/Arg305) promotes disengagement of the Ubl domain from RING1 and subsequent Parkin phosphorylation by PINK1; mutations mimicking pUb binding (releasing Ubl from RING1) promote Parkin phosphorylation and E3 ligase activity; SAXS and crystal structure at 2.54 Å of Parkin Δ86-130 used to define the binding switch.","method":"Mutagenesis, SAXS, 2.54 Å crystal structure, E2 (UbcH7) binding assays, E3 ligase activity assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus SAXS plus functional assays in a single study","pmids":["26254305"],"is_preprint":false},{"year":2008,"finding":"In Drosophila, the PINK1/Parkin pathway promotes mitochondrial fission: heterozygous loss of drp1 is largely lethal in PINK1 or parkin mutant background; flight muscle degeneration and mitochondrial morphology defects of PINK1/parkin mutants are suppressed by increased drp1 dosage and by heterozygous loss of fusion factors OPA1 and Mfn2, establishing PINK1/Parkin promote fission and that loss of fission underlies mutant phenotypes.","method":"Drosophila genetic epistasis, double-mutant analysis, mitochondrial morphology quantification","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in Drosophila ortholog with multiple allele combinations, 710 citations","pmids":["18230723"],"is_preprint":false},{"year":2018,"finding":"Parkin and PINK1 suppress STING-mediated inflammatory signaling: Prkn-/- and Pink1-/- mice develop strong inflammation following exhaustive exercise or mtDNA mutation accumulation; inflammation and dopaminergic neuron loss are rescued by concurrent STING loss, demonstrating PINK1/Parkin-mediated mitophagy restrains innate immunity by limiting cytosolic mtDNA-triggered STING activation.","method":"Knockout mouse models (Prkn-/-, Pink1-/-, Prkn-/-;STING-/-, Prkn-/-;mutator mice), cytokine measurements, dopaminergic neuron counts, genetic rescue","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — clean in vivo genetic epistasis with multiple KO combinations and defined molecular pathway, 1057 citations","pmids":["30135585"],"is_preprint":false},{"year":2016,"finding":"RABGEF1, an upstream factor of the endosomal Rab GTPase cascade, is recruited to damaged mitochondria via ubiquitin binding downstream of Parkin; RABGEF1 directs RAB5 and RAB7A to damaged mitochondria; RAB7A depletion inhibits ATG9A vesicle assembly and subsequent autophagosome encapsulation of mitochondria, revealing that Parkin-dependent endosomal Rab cycles regulate mitophagy by assembling ATG9A vesicles.","method":"siRNA knockdown, co-immunoprecipitation, live-cell imaging, ATG9A vesicle assembly assay in mammalian cells","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, multiple genetic perturbations, mechanistic pathway defined","pmids":["29360040"],"is_preprint":false},{"year":2016,"finding":"PINK1 phosphorylation of Miro on S156 promotes Parkin interaction with Miro, Miro ubiquitination and degradation, Parkin recruitment to mitochondria, and Parkin-dependent arrest of axonal mitochondrial transport; phosphomimetic Miro T298E/T299E inhibits PINK1-induced Miro ubiquitination, Parkin recruitment, and mitochondrial arrest.","method":"Phosphomimetic and non-phosphorylatable Miro mutants, co-immunoprecipitation, axonal transport imaging in neurons","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — phosphomimetic mutagenesis with functional cellular phenotype (axonal transport), Co-IP","pmids":["27679849"],"is_preprint":false},{"year":2020,"finding":"Parkin mediates both mono- and polyubiquitination of VDAC1 in a PINK1-dependent manner; VDAC1 polyubiquitination is required for mitophagy whereas VDAC1 monoubiquitination (K274) suppresses apoptosis by limiting mitochondrial calcium uptake through the MCU channel; a PD patient Parkin mutation T415N loses monoubiquitination but retains polyubiquitination capacity and fails to rescue PD phenotypes in Drosophila.","method":"Ubiquitination site mutagenesis, Drosophila transgenic models, mitophagy assays, apoptosis assays, mitochondrial calcium measurements","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis of specific ubiquitination sites with in vivo Drosophila validation and multiple cellular phenotype readouts","pmids":["32047033"],"is_preprint":false},{"year":2010,"finding":"Parkin directly binds Bcl-2 via its C terminus and mediates mono-ubiquitination of Bcl-2, increasing Bcl-2 steady-state levels and enhancing Bcl-2/Beclin-1 interaction to inhibit autophagy; overexpression of E3 ligase-deficient Parkin does not affect LC3 conversion, establishing E3 activity is required.","method":"Co-immunoprecipitation, in vitro ubiquitination assay, LC3 conversion assay, Parkin knockdown/overexpression","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP plus in vitro ubiquitination, ligase-dead mutant control, single lab","pmids":["20889974"],"is_preprint":false},{"year":2015,"finding":"Parkin interacts with APC/C coactivators Cdc20 and Cdh1 to mediate degradation of key mitotic regulators independently of APC/C; Parkin is phosphorylated and activated by Polo-like kinase 1 (Plk1) during mitosis; Parkin deficiency causes mitotic defects, genomic instability, and overexpression of mitotic substrates.","method":"Co-immunoprecipitation, in vitro ubiquitination assay, kinase assay (Plk1 phosphorylation of Parkin), Parkin knockout cell mitosis assays","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP and in vitro kinase/ubiquitination assays with defined cellular phenotype, single lab","pmids":["26387737"],"is_preprint":false},{"year":2016,"finding":"Parkin interacts with pyruvate kinase M2 (PKM2) both in vitro and in vivo; this interaction is increased during glucose starvation; Parkin ubiquitinates PKM2 without affecting its stability but decreases its enzymatic activity, thereby regulating glycolysis.","method":"Biochemical purification, co-immunoprecipitation, in vitro ubiquitination assay, PKM2 enzymatic activity assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro ubiquitination plus enzymatic activity assay plus Co-IP, single lab","pmids":["26975375"],"is_preprint":false},{"year":2018,"finding":"Parkin ubiquitinates Mfn2, and Parkin-dependent ubiquitination of Mfn2 regulates ER-mitochondria tethering; Parkin-deficient cells and parkin-mutant human fibroblasts show decreased ER-mitochondria contact; a non-ubiquitinatable Mfn2 mutant fails to restore ER-mitochondria physical and functional interaction; catalytically inactive Parkin has no effect on cytosolic Ca2+ transients.","method":"Confocal microscopy (ER-mitochondria contact quantification), Ca2+ flux measurements, Parkin KO mouse fibroblasts, patient fibroblasts, Mfn2 ubiquitination site mutagenesis, Drosophila in vivo locomotion rescue","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple cellular and in vivo readouts with mutagenesis, but mainly single lab","pmids":["30219582"],"is_preprint":false},{"year":2018,"finding":"Parkin mediates ubiquitination of VPS35 (retromer component) with atypical poly-ubiquitin chains at three C-terminal lysines; this ubiquitination does not promote proteasomal degradation of VPS35 but parkin knockout mice show marked decrease in WASH complex components and selective disruption of ATG9A vesicular sorting, suggesting Parkin modulates retromer-dependent endosomal sorting.","method":"Co-immunoprecipitation, in vitro ubiquitination assay, ubiquitin chain linkage analysis, parkin KO mouse brain fractionation, ATG9A trafficking assay in primary cortical neurons","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and cellular ubiquitination with defined cargo site mapping and KO phenotype, single lab","pmids":["29893854"],"is_preprint":false},{"year":2015,"finding":"USP8 deubiquitinase preferentially removes K6-linked ubiquitin conjugates from Parkin autoubiquitination; USP8 silencing causes persistence of K6-linked Ub conjugates on Parkin, delaying its translocation to damaged mitochondria and completion of mitophagy.","method":"Co-immunoprecipitation, ubiquitin linkage analysis, USP8 knockdown, quantitative mitophagy assay","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2–3 — Co-IP with defined linkage analysis and functional mitophagy readout, single lab","pmids":["25700639"],"is_preprint":false},{"year":2019,"finding":"USP33 localizes to the outer mitochondrial membrane, interacts with Parkin, and deubiquitinates Parkin in a DUB activity-dependent manner, preferentially removing K6, K11, K48, and K63-linked ubiquitin conjugates mainly at Lys435; USP33 knockdown increases Parkin protein stability and translocation to depolarized mitochondria, enhancing mitophagy.","method":"Co-immunoprecipitation, in vitro deubiquitination assay, ubiquitin linkage-specific analysis, Parkin translocation assay, quantitative mitophagy assay","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro DUB assay plus cellular functional assays with specific site identification, single lab","pmids":["31432739"],"is_preprint":false},{"year":2015,"finding":"Deubiquitinating enzymes USP30 and USP35 regulate Parkin-mediated mitophagy; USP30 delays mitophagy by delaying Parkin recruitment to mitochondria; USP35 regulates mitophagy through an alternative mechanism and translocates from mitochondria to cytosol during CCCP-induced mitophagy.","method":"Quantitative mitophagy assay, USP overexpression/knockdown, Parkin recruitment assay by live imaging","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 3 — functional assays with defined mitophagy phenotype but limited mechanistic detail for USP30 action on Parkin","pmids":["25915564"],"is_preprint":false},{"year":2021,"finding":"MITOL/MARCH5 ubiquitinates Parkin at lysine 220 to promote its proteasomal degradation; MITOL-mediated Parkin degradation fine-tunes mitophagy by controlling Parkin quantity; MITOL deletion leads to accumulation of phosphorylated active Parkin in the ER, causing FKBP38 degradation and enhanced cell death.","method":"Co-immunoprecipitation, in vitro ubiquitination assay, ubiquitination site mutagenesis (K220), proteasome inhibitor experiments, MITOL deletion cellular assays","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro ubiquitination with specific site identification and functional consequence, single lab","pmids":["33565245"],"is_preprint":false},{"year":2012,"finding":"Parkin and PINK1 are subject to neddylation (NEDD8 conjugation); neddylation of Parkin increases its E3 ligase activity; PD neurotoxin MPP+ inhibits neddylation of both Parkin and PINK1.","method":"In vitro neddylation assay, E3 ligase activity assay, Drosophila dAPP-BP1 overexpression epistasis, MPP+ treatment experiments","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro assay plus Drosophila genetic epistasis, single lab","pmids":["22388932"],"is_preprint":false},{"year":2008,"finding":"Combined phosphorylation of Parkin by casein kinase I and cyclin-dependent kinase 5 (Cdk5) decreases Parkin solubility, causing its aggregation and inactivation; combined kinase inhibition partially reverses aggregative properties of pathogenic Parkin point mutants; enhanced Parkin phosphorylation is detected in brain areas of sporadic PD patients and correlates with increased p25 (Cdk5 activator) levels.","method":"In vitro kinase assay, Parkin solubility/aggregation assay, kinase inhibitor treatment in cells, sporadic PD brain tissue analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro kinase assay plus cellular and postmortem tissue validation, single lab","pmids":["19050041"],"is_preprint":false},{"year":2019,"finding":"PHB2 stabilizes PINK1 on mitochondria via the PARL-PGAM5-PINK1 axis; PHB2 depletion destabilizes PINK1, blocking PRKN/Parkin recruitment to mitochondria; PHB2 overexpression directly induces Parkin recruitment; PHB2-mediated mitophagy is dependent on the inner membrane protease PARL and on PGAM5 processing by PARL.","method":"PHB2 knockdown/overexpression, PINK1 stability assay, Parkin translocation assay, PARL and PGAM5 genetic manipulation in mouse embryo fibroblasts","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 3 — functional pathway placement with multiple genetic perturbations but no in vitro reconstitution, single lab","pmids":["31177901"],"is_preprint":false},{"year":2018,"finding":"Miro1 interacts with a small pool of Parkin before mitochondrial damage in a PINK1-independent and ubiquitination-independent manner, serving as a calcium-sensitive docking site for Parkin on mitochondria; knockdown of Miro proteins reduces Parkin translocation to mitochondria and suppresses mitophagy; Miro1 EF-hand domains control Miro1 ubiquitination and Parkin recruitment.","method":"Co-immunoprecipitation, Miro knockdown, live-cell Parkin translocation assay, EF-hand domain mutagenesis","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2–3 — Co-IP plus functional knockdown with defined phenotype, but partial mechanistic follow-up on EF-hand domains","pmids":["30504269"],"is_preprint":false},{"year":2001,"finding":"Parkin functions as a RING-type E3 ubiquitin-protein ligase collaborating with E2 ubiquitin-conjugating enzymes UbcH7 and UbcH8; loss of this E3 ligase activity is the molecular basis of autosomal recessive juvenile parkinsonism.","method":"In vitro ubiquitin ligase assay, E2 enzyme specificity assay, pathogenic mutation functional analysis","journal":"Journal of molecular medicine (Berlin, Germany)","confidence":"High","confidence_rationale":"Tier 1 — in vitro E3 ligase reconstitution, foundational characterization widely replicated","pmids":["11692161"],"is_preprint":false},{"year":2009,"finding":"Parkin promotes DNA repair: parkin-deficient cells show reduced DNA excision repair restored by wild-type but not pathological mutant Parkin; Parkin interacts with PCNA (proliferating cell nuclear antigen), a coordinator of DNA excision repair; Parkin protects against DNA damage-induced cell death.","method":"DNA repair assay in parkin-deficient cells, transfection rescue with WT vs. mutant Parkin, co-immunoprecipitation with PCNA, cell death assay","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 — single lab, single Co-IP, limited mechanistic follow-up","pmids":["19285961"],"is_preprint":false},{"year":2015,"finding":"PARK2 physically interacts with β-catenin and EGFR and promotes their ubiquitination in an E3 ligase activity-dependent manner, downregulating Wnt- and EGF-stimulated pathways and inhibiting glioma cell growth.","method":"Co-immunoprecipitation, in vitro/cellular ubiquitination assay, PARK2 overexpression/knockdown in glioma cells, in vivo xenograft","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP plus ubiquitination assay with ligase-dead control and functional readout, single lab","pmids":["25877876"],"is_preprint":false},{"year":2016,"finding":"PARK2 directly binds to and ubiquitinates BCL-XL; PARK2 inactivation leads to aberrant accumulation of BCL-XL in vitro and in vivo; cancer-specific PARK2 mutations abrogate ubiquitination of BCL-XL; PARK2 modulates mitochondrial depolarization and apoptosis in a BCL-XL-dependent manner.","method":"Co-immunoprecipitation, in vitro ubiquitination assay, PARK2 KO mouse tissue, functional apoptosis assay","journal":"Neoplasia (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP plus in vitro ubiquitination plus in vivo KO, functional rescue, single lab","pmids":["28038320"],"is_preprint":false},{"year":2014,"finding":"In Drosophila, PINK1-mediated phosphorylation of Parkin at Ser94 (equivalent to human Ser65) boosts Parkin ubiquitin-ligase activity; phosphomimetic Parkin accelerates mitochondrial fragmentation/aggregation and mitochondrial protein degradation independently of PINK1 activity; non-phosphorylatable Parkin cannot rescue PINK1-null muscle phenotype fully; Parkin phosphorylation affects dopamine release and dopaminergic neuron survival in vivo.","method":"Drosophila transgenic models expressing phosphomimetic and non-phosphorylatable Parkin, mitochondrial morphology assay, dopamine release measurement, dopaminergic neuron survival quantification","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo Drosophila ortholog study with phosphomimetic mutagenesis and multiple functional readouts","pmids":["24901221"],"is_preprint":false},{"year":2023,"finding":"PRKN/Parkin ubiquitinates PA2G4/EBP1 at lysine 376 on damaged mitochondria; ubiquitinated PA2G4/EBP1 interacts with autophagy receptor SQSTM1/p62 to induce mitophagy; neuron-specific Pa2g4 knockout impairs mitophagy and worsens ischemia-reperfusion neuronal death.","method":"Ubiquitination site mutagenesis, co-immunoprecipitation, neuron-specific knockout mouse, ischemia-reperfusion model, AAV rescue","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — specific ubiquitination site identified with in vivo KO and functional rescue, single lab","pmids":["37712850"],"is_preprint":false},{"year":2023,"finding":"Under hypoxia, GPCPD1 (depalmitoylated by LYPLA1) relocates to the outer mitochondrial membrane and binds VDAC1, disrupting VDAC1 oligomerization; increased VDAC1 monomer provides more sites for PRKN-mediated polyubiquitination, triggering mitophagy.","method":"Co-immunoprecipitation, VDAC1 oligomerization assay, PRKN ubiquitination assay, GPCPD1 depalmitoylation assay, mitophagy quantification","journal":"Autophagy","confidence":"Low","confidence_rationale":"Tier 3 — Co-IP based mechanism with limited in vitro reconstitution, single lab","pmids":["36803235"],"is_preprint":false},{"year":2024,"finding":"Massively parallel variant abundance by sequencing (VAMP-seq) of 9219 Parkin variants in human cells shows most low-abundance variants are proteasome targets located in structured domains; a degron region proximal to the activation element (ACT) is mapped; missense variants cause degradation either by destabilizing the native protein or by introducing local degradation signals.","method":"VAMP-seq (variant abundance by massively parallel sequencing), proteasome inhibitor experiments, structural mapping of degrons","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — genome-scale functional assay with mechanistic structural interpretation, comprehensive coverage","pmids":["38378758"],"is_preprint":false}],"current_model":"PRKN encodes Parkin, an RBR-type E3 ubiquitin ligase that is normally autoinhibited; upon mitochondrial damage, PINK1 accumulates on the outer mitochondrial membrane and phosphorylates both ubiquitin (Ser65) and the Parkin Ubl domain (Ser65), causing phospho-ubiquitin to bind Parkin's RING1 domain and trigger sequential domain rearrangements (Ubl release → RING2 release) that open the active site; activated Parkin then ubiquitinates multiple outer mitochondrial membrane proteins (including Mfn1/2, VDAC1, Miro, and others), building phospho-ubiquitin chains that serve as the receptor for Parkin itself (feed-forward amplification) and recruit autophagy receptors (OPTN, NDP52) and ATG9A vesicles to initiate autophagosome formation around damaged mitochondria, thereby driving their lysosomal degradation (mitophagy) and preventing cytosolic mtDNA release and STING-dependent innate immune activation."},"narrative":{"teleology":[{"year":2001,"claim":"Establishing that Parkin is an E3 ubiquitin-protein ligase—and that loss of this activity underlies autosomal recessive juvenile parkinsonism—converted a genetically mapped disease locus into a defined enzymatic function.","evidence":"In vitro ubiquitin ligase reconstitution with E2 specificity profiling and pathogenic mutation analysis","pmids":["11692161"],"confidence":"High","gaps":["Physiological substrates unknown","Mechanism of autoinhibition not yet defined","No structural information"]},{"year":2008,"claim":"Discovery that Parkin selectively translocates to depolarized mitochondria and promotes their autophagic clearance established mitophagy as Parkin's central cellular function, while genetic epistasis in Drosophila placed PINK1/Parkin upstream of mitochondrial fission/fusion dynamics.","evidence":"Live-cell imaging and membrane-potential assays in mammalian cells; Drosophila double-mutant analysis with drp1, Opa1, Mfn2","pmids":["19029340","18230723"],"confidence":"High","gaps":["Upstream signal triggering Parkin recruitment unknown","Mechanism linking Parkin to fission machinery unclear","Identity of mitochondrial ubiquitin substrates not yet determined"]},{"year":2010,"claim":"Demonstrating that PINK1 accumulation on damaged mitochondria is both necessary and sufficient for Parkin recruitment established the PINK1→Parkin epistatic axis and explained how mitochondrial damage is sensed.","evidence":"Genetic epistasis with PINK1 overexpression/knockdown, disease mutations, and mitophagy assays in mammalian cells","pmids":["20126261"],"confidence":"High","gaps":["Biochemical mechanism of PINK1-mediated Parkin activation (phosphorylation target) unknown","Whether PINK1 directly phosphorylates Parkin or acts indirectly unresolved"]},{"year":2014,"claim":"Identification of Ser65-phosphorylated ubiquitin as a PINK1 product and allosteric Parkin activator revealed the dual-key activation mechanism (phospho-Ubl + phospho-ubiquitin) and explained how Parkin's latent E3 activity is unleashed on mitochondria.","evidence":"In vitro kinase assays, phosphopeptide mass spectrometry, ubiquitin-discharge assays with recombinant proteins; Drosophila phosphomimetic Parkin in vivo","pmids":["24784582","24901221"],"confidence":"High","gaps":["Structural basis for phospho-ubiquitin binding to Parkin undetermined","Full domain rearrangement upon activation not yet visualized"]},{"year":2015,"claim":"Crystal structures of Parkin–phospho-ubiquitin complexes, combined with the demonstration that phospho-ubiquitin chains serve as the mitochondrial Parkin receptor, defined the feed-forward amplification loop: Parkin builds ubiquitin chains → PINK1 phosphorylates them → phospho-Ub chains recruit more Parkin.","evidence":"X-ray crystallography (Pediculus Parkin–pUb complex), SAXS, cellular ubiquitin-replacement system, in vitro reconstitution with phosphomimetic tetra-ubiquitin","pmids":["26161729","25847540","26254305"],"confidence":"High","gaps":["Structure of fully activated human Parkin not yet solved","Catalytic RING2 domain release not structurally visualized","Relative contributions of different OMM substrates to amplification loop unclear"]},{"year":2018,"claim":"High-resolution structures of phosphorylated human Parkin and insect Parkin–E2 complexes revealed the complete two-step activation mechanism: phospho-Ubl rebinds to UPD via a disease-mutation-lined pocket, releasing RING2 and the ACT linker, exposing the catalytic cysteine.","evidence":"1.8 Å crystal structure of phosphorylated human Parkin, HDX-MS, NMR of activation intermediates, crystal structure of phosphorylated Bactrocera Parkin–pUb–E2 complex","pmids":["29995846","29967542"],"confidence":"High","gaps":["No structure of Parkin engaged with a mitochondrial substrate","Dynamics of membrane-proximal activation not captured"]},{"year":2015,"claim":"Identification of deubiquitinases USP8, USP30, and USP35 as regulators that oppose Parkin autoubiquitination and substrate ubiquitination established that mitophagy is tuned by an antagonistic DUB network, not solely by PINK1-Parkin activation.","evidence":"Ubiquitin-linkage analysis, USP knockdown/overexpression, quantitative mitophagy assays","pmids":["25700639","25915564"],"confidence":"Medium","gaps":["Relative physiological importance of each DUB in neurons undetermined","Structural basis for K6-linkage selectivity of USP8 on Parkin unknown","In vivo validation in mammalian models lacking"]},{"year":2016,"claim":"Demonstration that Parkin-dependent ubiquitination of Miro arrests axonal mitochondrial transport and that RABGEF1 recruitment to ubiquitinated mitochondria activates endosomal Rab cascades for ATG9A vesicle assembly connected Parkin's E3 activity to both mitochondrial motility arrest and autophagosome nucleation.","evidence":"Phosphomimetic Miro mutagenesis with axonal transport imaging; siRNA of RABGEF1/RAB7A with ATG9A vesicle assembly assays","pmids":["27679849","29360040"],"confidence":"High","gaps":["Whether Miro phosphorylation by PINK1 is the obligate trigger for Parkin-Miro interaction in all cell types is unclear","How ATG9A vesicles transition to LC3-positive autophagosomes at the mitochondrial surface not mechanistically resolved"]},{"year":2018,"claim":"Linking PINK1/Parkin-mediated mitophagy to suppression of STING-dependent innate immunity provided a direct pathogenic mechanism for neurodegeneration: in the absence of Parkin, cytosolic mtDNA accumulates and triggers neuroinflammation, which is rescued by STING deletion.","evidence":"Prkn−/−, Pink1−/−, and Prkn−/−;STING−/− knockout mice with exhaustive exercise and mutator backgrounds; cytokine measurements, dopaminergic neuron counts","pmids":["30135585"],"confidence":"High","gaps":["Whether STING-mediated inflammation is the primary driver of dopaminergic neuron loss in human PD is not established","Contribution of other innate immune sensors (cGAS, TLR9) to Parkin-loss phenotypes not delineated"]},{"year":2020,"claim":"Dissection of VDAC1 mono- versus polyubiquitination by Parkin separated mitophagy (polyubiquitination-dependent) from anti-apoptotic signaling (monoubiquitination at K274 suppresses MCU-mediated Ca²⁺ uptake), revealing that Parkin has ubiquitin-chain-type-specific, functionally distinct outputs on a single substrate.","evidence":"Ubiquitination site mutagenesis, mitophagy and apoptosis assays, mitochondrial calcium measurements, Drosophila transgenic rescue with PD-patient Parkin T415N mutant","pmids":["32047033"],"confidence":"High","gaps":["Whether this mono/polyUb distinction applies to other Parkin substrates untested","E2 enzyme(s) specifying chain type on VDAC1 not identified"]},{"year":2024,"claim":"Massively parallel functional profiling of ~9,200 Parkin variants mapped a degron near the ACT element and showed that most pathogenic missense variants cause protein instability and proteasomal degradation, unifying the genotype-phenotype landscape.","evidence":"VAMP-seq in human cells with proteasome inhibitor rescue and structural degron mapping","pmids":["38378758"],"confidence":"High","gaps":["Variant effects on enzymatic activity and mitophagy not measured in parallel","Whether degradation-prone variants can be pharmacologically stabilized in neurons is unknown"]},{"year":null,"claim":"Key unresolved questions include the structural basis for Parkin engagement with mitochondrial-membrane-embedded substrates, the relative contribution of individual substrates to mitophagy versus non-mitophagy functions in dopaminergic neurons, and whether pharmacological Parkin activation can be achieved therapeutically.","evidence":"","pmids":[],"confidence":"High","gaps":["No structure of membrane-engaged Parkin ubiquitinating a substrate","Substrate hierarchy on damaged mitochondria not systematically defined in neurons","No pharmacological Parkin activator validated in vivo"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,4,6,12,26,28,29,31]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[2,26,33]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,1,6,10,11,12]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[0,1,6,10,12,31]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,26,33]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[12,29]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[0,8]}],"complexes":[],"partners":["PINK1","VDAC1","MFN2","RHOT1","RHOT2","VPS35","USP30","USP33"],"other_free_text":[]},"mechanistic_narrative":"PRKN encodes Parkin, an RBR-type E3 ubiquitin-protein ligase that is the principal effector of PINK1-directed mitophagy and a cause of autosomal recessive juvenile parkinsonism when mutationally inactivated [PMID:11692161, PMID:19029340]. Parkin is normally autoinhibited in the cytosol; upon mitochondrial depolarization, PINK1 accumulates on the outer mitochondrial membrane and phosphorylates ubiquitin at Ser65, which binds a conserved pocket in Parkin's RING1 domain, displacing the Ubl domain and triggering sequential release of the catalytic RING2 domain to expose the active-site cysteine [PMID:24784582, PMID:26161729, PMID:29995846]. Activated Parkin ubiquitinates outer mitochondrial membrane substrates including Mfn2, VDAC1, and Miro, building phospho-ubiquitin chains that recruit additional Parkin (feed-forward amplification) and autophagy adaptors to drive autophagosome assembly around damaged mitochondria; failure of this pathway leads to cytosolic mtDNA release and STING-dependent neuroinflammation, linking Parkin loss to dopaminergic neurodegeneration [PMID:25847540, PMID:32047033, PMID:27679849, PMID:30135585]. Beyond mitophagy, Parkin ubiquitinates diverse substrates including BCL-XL, β-catenin, EGFR, and PKM2, contributing to apoptosis regulation, cell-cycle control, and metabolic homeostasis [PMID:28038320, PMID:25877876, PMID:26975375]."},"prefetch_data":{"uniprot":{"accession":"O60260","full_name":"E3 ubiquitin-protein ligase parkin","aliases":["Parkin RBR E3 ubiquitin-protein ligase","Parkinson juvenile disease protein 2","Parkinson disease protein 2"],"length_aa":465,"mass_kda":51.6,"function":"Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins (PubMed:10888878, PubMed:10973942, PubMed:11431533, PubMed:12150907, PubMed:12628165, PubMed:15105460, PubMed:16135753, PubMed:21376232, PubMed:21532592, PubMed:22396657, PubMed:23620051, PubMed:23754282, PubMed:24660806, PubMed:24751536, PubMed:29311685, PubMed:32047033). Substrates include SYT11 and VDAC1 (PubMed:29311685, PubMed:32047033). Other substrates are BCL2, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, SNCAIP, SEPTIN5, TOMM20, USP30, ZNF746, MIRO1 and AIMP2 (PubMed:10888878, PubMed:10973942, PubMed:11431533, PubMed:12150907, PubMed:12628165, PubMed:15105460, PubMed:16135753, PubMed:21376232, PubMed:21532592, PubMed:22396657, PubMed:23620051, PubMed:23754282, PubMed:24660806, PubMed:24751536). Mediates monoubiquitination as well as 'Lys-6', 'Lys-11', 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context (PubMed:19229105, PubMed:20889974, PubMed:25474007, PubMed:25621951, PubMed:32047033). Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation (PubMed:17846173, PubMed:19229105). Mediates 'Lys-63'-linked polyubiquitination of a 22 kDa O-linked glycosylated isoform of SNCAIP, possibly playing a role in Lewy-body formation (PubMed:11431533, PubMed:11590439, PubMed:15105460, PubMed:15728840, PubMed:19229105). Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy (PubMed:20889974). Protects against mitochondrial dysfunction during cellular stress, by acting downstream of PINK1 to coordinate mitochondrial quality control mechanisms that remove and replace dysfunctional mitochondrial components (PubMed:11439185, PubMed:18957282, PubMed:19029340, PubMed:19966284, PubMed:21376232, PubMed:22082830, PubMed:22396657, PubMed:23620051, PubMed:23933751, PubMed:24660806, PubMed:24784582, PubMed:24896179, PubMed:25474007, PubMed:25527291, PubMed:32047033). Depending on the severity of mitochondrial damage and/or dysfunction, activity ranges from preventing apoptosis and stimulating mitochondrial biogenesis to regulating mitochondrial dynamics and eliminating severely damaged mitochondria via mitophagy (PubMed:11439185, PubMed:19029340, PubMed:19801972, PubMed:19966284, PubMed:21376232, PubMed:22082830, PubMed:22396657, PubMed:23620051, PubMed:23685073, PubMed:23933751, PubMed:24896179, PubMed:25527291, PubMed:32047033, PubMed:33499712). Activation and recruitment onto the outer membrane of damaged/dysfunctional mitochondria (OMM) requires PINK1-mediated phosphorylation of both PRKN and ubiquitin (PubMed:24660806, PubMed:24784582, PubMed:25474007, PubMed:25527291). After mitochondrial damage, functions with PINK1 to mediate the decision between mitophagy or preventing apoptosis by inducing either the poly- or monoubiquitination of VDAC1, respectively; polyubiquitination of VDAC1 promotes mitophagy, while monoubiquitination of VDAC1 decreases mitochondrial calcium influx which ultimately inhibits apoptosis (PubMed:27534820, PubMed:32047033). When cellular stress results in irreversible mitochondrial damage, promotes the autophagic degradation of dysfunctional depolarized mitochondria (mitophagy) by promoting the ubiquitination of mitochondrial proteins such as TOMM20, RHOT1/MIRO1, MFN1 and USP30 (PubMed:19029340, PubMed:19966284, PubMed:21753002, PubMed:22396657, PubMed:23620051, PubMed:23685073, PubMed:23933751, PubMed:24896179, PubMed:25527291). Preferentially assembles 'Lys-6'-, 'Lys-11'- and 'Lys-63'-linked polyubiquitin chains, leading to mitophagy (PubMed:25621951, PubMed:32047033). The PINK1-PRKN pathway also promotes fission of damaged mitochondria by PINK1-mediated phosphorylation which promotes the PRKN-dependent degradation of mitochondrial proteins involved in fission such as MFN2 (PubMed:23620051). This prevents the refusion of unhealthy mitochondria with the mitochondrial network or initiates mitochondrial fragmentation facilitating their later engulfment by autophagosomes (PubMed:23620051). Regulates motility of damaged mitochondria via the ubiquitination and subsequent degradation of MIRO1 and MIRO2; in motor neurons, this likely inhibits mitochondrial intracellular anterograde transport along the axons which probably increases the chance of the mitochondria undergoing mitophagy in the soma (PubMed:22396657). Involved in mitochondrial biogenesis via the 'Lys-48'-linked polyubiquitination of transcriptional repressor ZNF746/PARIS which leads to its subsequent proteasomal degradation and allows activation of the transcription factor PPARGC1A (PubMed:21376232). Limits the production of reactive oxygen species (ROS) (PubMed:18541373). Regulates cyclin-E during neuronal apoptosis (PubMed:12628165). In collaboration with CHPF isoform 2, may enhance cell viability and protect cells from oxidative stress (PubMed:22082830). Independently of its ubiquitin ligase activity, protects from apoptosis by the transcriptional repression of p53/TP53 (PubMed:19801972). May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity (PubMed:11439185). May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. May represent a tumor suppressor gene (PubMed:12719539)","subcellular_location":"Cytoplasm, cytosol; Nucleus; Endoplasmic reticulum; Mitochondrion; Mitochondrion outer membrane; Cell projection, neuron projection; Postsynaptic density; Presynapse","url":"https://www.uniprot.org/uniprotkb/O60260/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRKN","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PRKN","total_profiled":1310},"omim":[{"mim_id":"620808","title":"SMALL NUCLEOLAR RNA HOST GENE 17; SNHG17","url":"https://www.omim.org/entry/620808"},{"mim_id":"620069","title":"ANKYRIN REPEAT- AND IBR DOMAIN-CONTAINING PROTEIN 1; ANKIB1","url":"https://www.omim.org/entry/620069"},{"mim_id":"617081","title":"OMA1 ZINC METALLOPEPTIDASE; OMA1","url":"https://www.omim.org/entry/617081"},{"mim_id":"616032","title":"FOCAL SEGMENTAL GLOMERULOSCLEROSIS 8; FSGS8","url":"https://www.omim.org/entry/616032"},{"mim_id":"616027","title":"ACTIN-BINDING PROTEIN ANILLIN; ANLN","url":"https://www.omim.org/entry/616027"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear speckles","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"skeletal muscle","ntpm":26.6},{"tissue":"tongue","ntpm":14.8}],"url":"https://www.proteinatlas.org/search/PRKN"},"hgnc":{"alias_symbol":["PDJ","AR-JP","parkin"],"prev_symbol":["PARK2"]},"alphafold":{"accession":"O60260","domains":[{"cath_id":"3.10.20.90","chopping":"1-70","consensus_level":"high","plddt":87.3554,"start":1,"end":70},{"cath_id":"-","chopping":"247-364","consensus_level":"medium","plddt":88.7677,"start":247,"end":364},{"cath_id":"2.20.25","chopping":"414-460","consensus_level":"medium","plddt":87.8834,"start":414,"end":460}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O60260","model_url":"https://alphafold.ebi.ac.uk/files/AF-O60260-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O60260-F1-predicted_aligned_error_v6.png","plddt_mean":78.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRKN","jax_strain_url":"https://www.jax.org/strain/search?query=PRKN"},"sequence":{"accession":"O60260","fasta_url":"https://rest.uniprot.org/uniprotkb/O60260.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O60260/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O60260"}},"corpus_meta":[{"pmid":"19029340","id":"PMC_19029340","title":"Parkin is recruited selectively to impaired mitochondria and promotes their autophagy.","date":"2008","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19029340","citation_count":3295,"is_preprint":false},{"pmid":"20126261","id":"PMC_20126261","title":"PINK1 is selectively stabilized on impaired mitochondria to activate Parkin.","date":"2010","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/20126261","citation_count":2377,"is_preprint":false},{"pmid":"24784582","id":"PMC_24784582","title":"Ubiquitin is phosphorylated by PINK1 to activate parkin.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24784582","citation_count":1199,"is_preprint":false},{"pmid":"30135585","id":"PMC_30135585","title":"Parkin and PINK1 mitigate STING-induced inflammation.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/30135585","citation_count":1057,"is_preprint":false},{"pmid":"18230723","id":"PMC_18230723","title":"The PINK1/Parkin pathway regulates mitochondrial morphology.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18230723","citation_count":710,"is_preprint":false},{"pmid":"26161729","id":"PMC_26161729","title":"Mechanism of phospho-ubiquitin-induced PARKIN activation.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26161729","citation_count":388,"is_preprint":false},{"pmid":"33168089","id":"PMC_33168089","title":"PINK1/PARKIN signalling in neurodegeneration and neuroinflammation.","date":"2020","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/33168089","citation_count":368,"is_preprint":false},{"pmid":"31177901","id":"PMC_31177901","title":"PHB2 (prohibitin 2) promotes PINK1-PRKN/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/31177901","citation_count":334,"is_preprint":false},{"pmid":"29995846","id":"PMC_29995846","title":"Mechanism of parkin activation by PINK1.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29995846","citation_count":306,"is_preprint":false},{"pmid":"21194381","id":"PMC_21194381","title":"Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control.","date":"2011","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/21194381","citation_count":294,"is_preprint":false},{"pmid":"28437683","id":"PMC_28437683","title":"PINK1 and Parkin: emerging themes in mitochondrial homeostasis.","date":"2017","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28437683","citation_count":269,"is_preprint":false},{"pmid":"27094585","id":"PMC_27094585","title":"Mechanisms of mitophagy: PINK1, Parkin, USP30 and beyond.","date":"2016","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27094585","citation_count":261,"is_preprint":false},{"pmid":"29172924","id":"PMC_29172924","title":"PINK1-PRKN/PARK2 pathway of mitophagy is activated to protect against renal ischemia-reperfusion injury.","date":"2018","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/29172924","citation_count":253,"is_preprint":false},{"pmid":"27593930","id":"PMC_27593930","title":"Parkin and mitophagy in cancer.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27593930","citation_count":231,"is_preprint":false},{"pmid":"25847540","id":"PMC_25847540","title":"Phosphorylated ubiquitin chain is the genuine Parkin receptor.","date":"2015","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25847540","citation_count":225,"is_preprint":false},{"pmid":"30100261","id":"PMC_30100261","title":"PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism.","date":"2018","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/30100261","citation_count":221,"is_preprint":false},{"pmid":"33570005","id":"PMC_33570005","title":"Regulation of PRKN-independent mitophagy.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/33570005","citation_count":199,"is_preprint":false},{"pmid":"25712550","id":"PMC_25712550","title":"Parkin structure and function.","date":"2015","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/25712550","citation_count":190,"is_preprint":false},{"pmid":"30290714","id":"PMC_30290714","title":"PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis.","date":"2018","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/30290714","citation_count":187,"is_preprint":false},{"pmid":"30115557","id":"PMC_30115557","title":"No Parkin Zone: Mitophagy without Parkin.","date":"2018","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30115557","citation_count":186,"is_preprint":false},{"pmid":"25915564","id":"PMC_25915564","title":"Deubiquitinating enzymes regulate PARK2-mediated mitophagy.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25915564","citation_count":185,"is_preprint":false},{"pmid":"32047033","id":"PMC_32047033","title":"Decision between mitophagy and apoptosis by Parkin via VDAC1 ubiquitination.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32047033","citation_count":183,"is_preprint":false},{"pmid":"30219582","id":"PMC_30219582","title":"Regulation of ER-mitochondria contacts by Parkin via Mfn2.","date":"2018","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/30219582","citation_count":179,"is_preprint":false},{"pmid":"26254305","id":"PMC_26254305","title":"A Ubl/ubiquitin switch in the activation of Parkin.","date":"2015","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/26254305","citation_count":166,"is_preprint":false},{"pmid":"21187721","id":"PMC_21187721","title":"Regulation of PINK1-Parkin-mediated mitophagy.","date":"2011","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/21187721","citation_count":153,"is_preprint":false},{"pmid":"29967542","id":"PMC_29967542","title":"Mechanism of parkin activation by phosphorylation.","date":"2018","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29967542","citation_count":144,"is_preprint":false},{"pmid":"33137712","id":"PMC_33137712","title":"The PINK1/PARK2/optineurin pathway of mitophagy is activated for protection in septic acute kidney injury.","date":"2020","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/33137712","citation_count":143,"is_preprint":false},{"pmid":"31339428","id":"PMC_31339428","title":"SQSTM1/p62 promotes mitochondrial ubiquitination independently of PINK1 and PRKN/parkin in mitophagy.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/31339428","citation_count":142,"is_preprint":false},{"pmid":"20889974","id":"PMC_20889974","title":"Parkin mono-ubiquitinates Bcl-2 and regulates autophagy.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20889974","citation_count":142,"is_preprint":false},{"pmid":"34720029","id":"PMC_34720029","title":"Newcastle disease virus degrades SIRT3 via PINK1-PRKN-dependent mitophagy to reprogram energy metabolism in infected cells.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34720029","citation_count":141,"is_preprint":false},{"pmid":"33029617","id":"PMC_33029617","title":"Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism.","date":"2020","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33029617","citation_count":139,"is_preprint":false},{"pmid":"29360040","id":"PMC_29360040","title":"Endosomal Rab cycles regulate Parkin-mediated mitophagy.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/29360040","citation_count":138,"is_preprint":false},{"pmid":"27679849","id":"PMC_27679849","title":"Miro phosphorylation sites regulate Parkin recruitment and mitochondrial motility.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27679849","citation_count":132,"is_preprint":false},{"pmid":"24878071","id":"PMC_24878071","title":"Functional interplay between Parkin and Drp1 in mitochondrial fission and clearance.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24878071","citation_count":131,"is_preprint":false},{"pmid":"27206984","id":"PMC_27206984","title":"The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27206984","citation_count":125,"is_preprint":false},{"pmid":"28017782","id":"PMC_28017782","title":"Parkin and PINK1 functions in oxidative stress and neurodegeneration.","date":"2016","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/28017782","citation_count":122,"is_preprint":false},{"pmid":"31982458","id":"PMC_31982458","title":"The PINK1-Parkin axis: An Overview.","date":"2020","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/31982458","citation_count":112,"is_preprint":false},{"pmid":"30504269","id":"PMC_30504269","title":"Miro proteins prime mitochondria for Parkin translocation and mitophagy.","date":"2018","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/30504269","citation_count":110,"is_preprint":false},{"pmid":"31432739","id":"PMC_31432739","title":"USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/31432739","citation_count":108,"is_preprint":false},{"pmid":"31825802","id":"PMC_31825802","title":"Drp1-regulated PARK2-dependent mitophagy protects against renal fibrosis in unilateral ureteral obstruction.","date":"2019","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31825802","citation_count":101,"is_preprint":false},{"pmid":"25801386","id":"PMC_25801386","title":"Temporal dynamics of PARK2/parkin and OPTN/optineurin recruitment during the mitophagy of damaged mitochondria.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25801386","citation_count":98,"is_preprint":false},{"pmid":"15229644","id":"PMC_15229644","title":"How does parkin ligate ubiquitin to Parkinson's disease?","date":"2004","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/15229644","citation_count":96,"is_preprint":false},{"pmid":"15189352","id":"PMC_15189352","title":"Parkin attenuates manganese-induced dopaminergic cell death.","date":"2004","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15189352","citation_count":95,"is_preprint":false},{"pmid":"26975375","id":"PMC_26975375","title":"Parkin Regulates the Activity of Pyruvate Kinase M2.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26975375","citation_count":95,"is_preprint":false},{"pmid":"30386443","id":"PMC_30386443","title":"PINK1-PARK2-mediated mitophagy in COPD and IPF pathogeneses.","date":"2018","source":"Inflammation and regeneration","url":"https://pubmed.ncbi.nlm.nih.gov/30386443","citation_count":93,"is_preprint":false},{"pmid":"37207627","id":"PMC_37207627","title":"Unconventional initiation of PINK1/Parkin mitophagy by Optineurin.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/37207627","citation_count":90,"is_preprint":false},{"pmid":"15571819","id":"PMC_15571819","title":"Ubiquitin, proteasome and parkin.","date":"2004","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15571819","citation_count":87,"is_preprint":false},{"pmid":"27754761","id":"PMC_27754761","title":"A novel PINK1- and PARK2-dependent protective neuroimmune pathway in lethal sepsis.","date":"2016","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/27754761","citation_count":85,"is_preprint":false},{"pmid":"26387737","id":"PMC_26387737","title":"Parkin Regulates Mitosis and Genomic Stability through Cdc20/Cdh1.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26387737","citation_count":78,"is_preprint":false},{"pmid":"14727181","id":"PMC_14727181","title":"Genetics of parkin-linked disease.","date":"2004","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14727181","citation_count":70,"is_preprint":false},{"pmid":"16734611","id":"PMC_16734611","title":"PARK2/PACRG polymorphisms and susceptibility to typhoid and paratyphoid fever.","date":"2006","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16734611","citation_count":69,"is_preprint":false},{"pmid":"22388932","id":"PMC_22388932","title":"Regulation of parkin and PINK1 by neddylation.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22388932","citation_count":65,"is_preprint":false},{"pmid":"25640678","id":"PMC_25640678","title":"A recurrent mutation in PARK2 is associated with familial lung cancer.","date":"2015","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25640678","citation_count":61,"is_preprint":false},{"pmid":"33572534","id":"PMC_33572534","title":"Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson's Disease.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33572534","citation_count":60,"is_preprint":false},{"pmid":"24901221","id":"PMC_24901221","title":"PINK1-mediated phosphorylation of Parkin boosts Parkin activity in Drosophila.","date":"2014","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24901221","citation_count":59,"is_preprint":false},{"pmid":"36803235","id":"PMC_36803235","title":"Hypoxia-induced GPCPD1 depalmitoylation triggers mitophagy via regulating PRKN-mediated ubiquitination of VDAC1.","date":"2023","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36803235","citation_count":58,"is_preprint":false},{"pmid":"11692161","id":"PMC_11692161","title":"Parkin is linked to the ubiquitin pathway.","date":"2001","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/11692161","citation_count":58,"is_preprint":false},{"pmid":"34671015","id":"PMC_34671015","title":"GAK and PRKCD are positive regulators of PRKN-independent mitophagy.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34671015","citation_count":57,"is_preprint":false},{"pmid":"33685343","id":"PMC_33685343","title":"Mt-Keima detects PINK1-PRKN mitophagy in vivo with greater sensitivity than mito-QC.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/33685343","citation_count":56,"is_preprint":false},{"pmid":"29893854","id":"PMC_29893854","title":"Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29893854","citation_count":55,"is_preprint":false},{"pmid":"30074231","id":"PMC_30074231","title":"Loss of Microglial Parkin Inhibits Necroptosis and Contributes to Neuroinflammation.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30074231","citation_count":54,"is_preprint":false},{"pmid":"35460111","id":"PMC_35460111","title":"Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation.","date":"2022","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/35460111","citation_count":53,"is_preprint":false},{"pmid":"31333417","id":"PMC_31333417","title":"PARK2 Mutation Causes Metabolic Disturbances and Impaired Survival of Human iPSC-Derived Neurons.","date":"2019","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31333417","citation_count":51,"is_preprint":false},{"pmid":"33448283","id":"PMC_33448283","title":"Assessing the relationship between monoallelic PRKN mutations and Parkinson's risk.","date":"2021","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33448283","citation_count":51,"is_preprint":false},{"pmid":"26188007","id":"PMC_26188007","title":"Heterozygote carriers for CNVs in PARK2 are at increased risk of Parkinson's disease.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26188007","citation_count":51,"is_preprint":false},{"pmid":"19050041","id":"PMC_19050041","title":"Combined kinase inhibition modulates parkin inactivation.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19050041","citation_count":50,"is_preprint":false},{"pmid":"25877876","id":"PMC_25877876","title":"Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25877876","citation_count":50,"is_preprint":false},{"pmid":"15078880","id":"PMC_15078880","title":"N-myc regulates parkin expression.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15078880","citation_count":47,"is_preprint":false},{"pmid":"28962651","id":"PMC_28962651","title":"Hexokinases link DJ-1 to the PINK1/parkin pathway.","date":"2017","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/28962651","citation_count":46,"is_preprint":false},{"pmid":"30252570","id":"PMC_30252570","title":"Mitochondrial quality control mediated by PINK1 and PRKN: links to iron metabolism and tumor immunity.","date":"2018","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/30252570","citation_count":46,"is_preprint":false},{"pmid":"25689131","id":"PMC_25689131","title":"Chemogenomic profiling of endogenous PARK2 expression using a genome-edited coincidence reporter.","date":"2015","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/25689131","citation_count":44,"is_preprint":false},{"pmid":"28222786","id":"PMC_28222786","title":"Post translational modification of Parkin.","date":"2017","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/28222786","citation_count":43,"is_preprint":false},{"pmid":"15194120","id":"PMC_15194120","title":"How do Parkin mutations result in neurodegeneration?","date":"2004","source":"Current opinion in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/15194120","citation_count":43,"is_preprint":false},{"pmid":"37712850","id":"PMC_37712850","title":"PA2G4/EBP1 ubiquitination by PRKN/PARKIN promotes mitophagy protecting neuron death in cerebral ischemia.","date":"2023","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/37712850","citation_count":42,"is_preprint":false},{"pmid":"38553467","id":"PMC_38553467","title":"Genotype-phenotype correlation in PRKN-associated Parkinson's disease.","date":"2024","source":"NPJ Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/38553467","citation_count":42,"is_preprint":false},{"pmid":"29515107","id":"PMC_29515107","title":"PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29515107","citation_count":42,"is_preprint":false},{"pmid":"30911576","id":"PMC_30911576","title":"Metabolomics-based identification of metabolic alterations in PARK2.","date":"2019","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30911576","citation_count":42,"is_preprint":false},{"pmid":"25700639","id":"PMC_25700639","title":"USP8 and PARK2/parkin-mediated mitophagy.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25700639","citation_count":41,"is_preprint":false},{"pmid":"32297878","id":"PMC_32297878","title":"PINK1 and Parkin: team players in stress-induced mitophagy.","date":"2020","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32297878","citation_count":41,"is_preprint":false},{"pmid":"25849928","id":"PMC_25849928","title":"Activation of the E3 ubiquitin ligase Parkin.","date":"2015","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/25849928","citation_count":40,"is_preprint":false},{"pmid":"33298969","id":"PMC_33298969","title":"Reduced astrocytic reactivity in human brains and midbrain organoids with PRKN mutations.","date":"2020","source":"NPJ Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/33298969","citation_count":39,"is_preprint":false},{"pmid":"25553463","id":"PMC_25553463","title":"Functions and characteristics of PINK1 and Parkin in cancer.","date":"2015","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/25553463","citation_count":38,"is_preprint":false},{"pmid":"32892694","id":"PMC_32892694","title":"Two different axes CALCOCO2-RB1CC1 and OPTN-ATG9A initiate PRKN-mediated mitophagy.","date":"2020","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/32892694","citation_count":38,"is_preprint":false},{"pmid":"27794540","id":"PMC_27794540","title":"PINK1 and Parkin are genetic modifiers for FUS-induced neurodegeneration.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27794540","citation_count":38,"is_preprint":false},{"pmid":"28620835","id":"PMC_28620835","title":"Twenty years since the discovery of the parkin gene.","date":"2017","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/28620835","citation_count":37,"is_preprint":false},{"pmid":"22028146","id":"PMC_22028146","title":"Restriction of trophic factors and nutrients induces PARKIN expression.","date":"2011","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22028146","citation_count":37,"is_preprint":false},{"pmid":"28335015","id":"PMC_28335015","title":"The synaptic function of parkin.","date":"2017","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28335015","citation_count":36,"is_preprint":false},{"pmid":"24162069","id":"PMC_24162069","title":"The reciprocal roles of PARK2 and mitofusins in mitophagy and mitochondrial spheroid formation.","date":"2013","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/24162069","citation_count":36,"is_preprint":false},{"pmid":"19285961","id":"PMC_19285961","title":"Regulation of DNA repair by parkin.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19285961","citation_count":35,"is_preprint":false},{"pmid":"23939304","id":"PMC_23939304","title":"Loss-of-function rodent models for parkin and PINK1.","date":"2011","source":"Journal of Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/23939304","citation_count":35,"is_preprint":false},{"pmid":"33565245","id":"PMC_33565245","title":"MITOL promotes cell survival by degrading Parkin during mitophagy.","date":"2021","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/33565245","citation_count":34,"is_preprint":false},{"pmid":"38378758","id":"PMC_38378758","title":"A mutational atlas for Parkin proteostasis.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38378758","citation_count":31,"is_preprint":false},{"pmid":"31508359","id":"PMC_31508359","title":"PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31508359","citation_count":31,"is_preprint":false},{"pmid":"37926948","id":"PMC_37926948","title":"Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.","date":"2023","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/37926948","citation_count":31,"is_preprint":false},{"pmid":"25656612","id":"PMC_25656612","title":"Expression pattern of parkin isoforms in lung adenocarcinomas.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25656612","citation_count":29,"is_preprint":false},{"pmid":"35123805","id":"PMC_35123805","title":"Genotype-phenotype correlation of Parkinson's disease with PRKN variants.","date":"2022","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/35123805","citation_count":29,"is_preprint":false},{"pmid":"20629119","id":"PMC_20629119","title":"Nonmotor symptoms in Parkin gene-related parkinsonism.","date":"2010","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/20629119","citation_count":29,"is_preprint":false},{"pmid":"28038320","id":"PMC_28038320","title":"Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis.","date":"2016","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28038320","citation_count":28,"is_preprint":false},{"pmid":"39854875","id":"PMC_39854875","title":"Histone lactylation regulates PRKN-Mediated mitophagy to promote M2 Macrophage polarization in bladder cancer.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39854875","citation_count":27,"is_preprint":false},{"pmid":"30697141","id":"PMC_30697141","title":"The Transcription Factor Function of Parkin: Breaking the Dogma.","date":"2019","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30697141","citation_count":27,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48636,"output_tokens":8493,"usd":0.136652},"stage2":{"model":"claude-opus-4-6","input_tokens":12266,"output_tokens":3374,"usd":0.21852},"total_usd":0.355172,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"Parkin is selectively recruited from the cytosol to dysfunctional mitochondria with low membrane potential, where it mediates engulfment of mitochondria by autophagosomes and promotes selective elimination of impaired mitochondria (mitophagy).\",\n      \"method\": \"Live-cell imaging, mitochondrial membrane potential assays, autophagosome colocalization in mammalian cells\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational discovery, highly cited (3295 citations), multiple orthogonal methods, replicated across many subsequent studies\",\n      \"pmids\": [\"19029340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PINK1 accumulation on damaged mitochondria (regulated by voltage-dependent proteolysis that keeps PINK1 low on healthy mitochondria) is both necessary and sufficient for Parkin recruitment to mitochondria; disease-causing mutations in PINK1 and Parkin disrupt Parkin recruitment and Parkin-induced mitophagy at distinct steps, establishing PINK1 acts upstream of Parkin.\",\n      \"method\": \"Genetic epistasis in mammalian cells, dominant-negative and loss-of-function mutations, PINK1 overexpression/knockdown, mitophagy assays\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational epistasis and biochemical study with multiple orthogonal methods, 2377 citations, widely replicated\",\n      \"pmids\": [\"20126261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PINK1 phosphorylates ubiquitin at Ser65 both in vitro and in cells; phosphorylated ubiquitin (phosphoUb) acts as an allosteric activator of Parkin E3 ligase activity by accelerating discharge of the UbcH7~ubiquitin thioester conjugate; PINK1-dependent phosphorylation of both Parkin and ubiquitin is sufficient for full activation of Parkin E3 activity.\",\n      \"method\": \"In vitro kinase assay, phosphopeptide mass spectrometry, in vitro ubiquitin discharge assay with recombinant proteins, phosphomimetic ubiquitin rescue experiments in cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis, replicated by multiple groups, 1199 citations\",\n      \"pmids\": [\"24784582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of Pediculus humanus Parkin in complex with Ser65-phosphorylated ubiquitin reveals the molecular basis for Parkin recruitment and activation: phosphoUb binds a conserved phosphate pocket in RING1 (involving AR-JP mutation residues), straightens a RING1 helix causing conformational changes that release the Ubl domain from the Parkin core, activating Parkin; phosphoUb-mediated Ubl release also enhances Ubl phosphorylation by PINK1, stabilizing an open active conformation.\",\n      \"method\": \"Crystal structure (X-ray crystallography), mutagenesis, biochemical binding assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation and mutagenesis of AR-JP disease mutations\",\n      \"pmids\": [\"26161729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Full-length human Parkin undergoes large-scale domain rearrangement upon activation: phospho-Ubl rebinds to the Parkin core (UPD domain via a phosphate-binding pocket lined by AR-JP mutations) and releases the catalytic RING2 domain; a conserved linker region (ACT element) between Ubl and UPD mimics RING2 interactions to aid RING2 release; 1.8 Å crystal structure of phosphorylated human Parkin determined.\",\n      \"method\": \"Hydrogen-deuterium exchange mass spectrometry, 1.8 Å crystal structure of phosphorylated human Parkin, mutagenesis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure combined with HDX-MS and mutagenesis in a single rigorous study\",\n      \"pmids\": [\"29995846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structure of phosphorylated Bactrocera dorsalis Parkin in complex with phosphorylated ubiquitin and an E2 ubiquitin-conjugating enzyme reveals that the key activating step is movement of the Ubl domain and release of the catalytic RING2 domain; HDX and NMR experiments with activation intermediates confirm large domain movements in mammalian Parkin activation.\",\n      \"method\": \"Crystal structure (X-ray crystallography), hydrogen/deuterium exchange, NMR, mutagenesis\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with orthogonal biophysical methods validating the activation mechanism\",\n      \"pmids\": [\"29967542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Phosphorylated ubiquitin chain (not monomeric phosphoUb) is the genuine Parkin receptor on mitochondria: linear phosphomimetic tetra-ubiquitin(S65D) recruits Parkin to energized mitochondria in absence of PINK1; physical interaction between phosphomimetic Parkin and phosphorylated polyubiquitin chain detected by Co-IP from cells and by in vitro reconstitution with recombinant proteins.\",\n      \"method\": \"Cellular ubiquitin replacement system, Co-IP from cells, in vitro reconstitution with recombinant proteins, lysosomal phosphorylated polyubiquitin chain recruitment assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro reconstitution plus cellular rescue experiments with orthogonal approaches\",\n      \"pmids\": [\"25847540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Phospho-ubiquitin binding to RING1 of Parkin (at His302/Arg305) promotes disengagement of the Ubl domain from RING1 and subsequent Parkin phosphorylation by PINK1; mutations mimicking pUb binding (releasing Ubl from RING1) promote Parkin phosphorylation and E3 ligase activity; SAXS and crystal structure at 2.54 Å of Parkin Δ86-130 used to define the binding switch.\",\n      \"method\": \"Mutagenesis, SAXS, 2.54 Å crystal structure, E2 (UbcH7) binding assays, E3 ligase activity assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus SAXS plus functional assays in a single study\",\n      \"pmids\": [\"26254305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In Drosophila, the PINK1/Parkin pathway promotes mitochondrial fission: heterozygous loss of drp1 is largely lethal in PINK1 or parkin mutant background; flight muscle degeneration and mitochondrial morphology defects of PINK1/parkin mutants are suppressed by increased drp1 dosage and by heterozygous loss of fusion factors OPA1 and Mfn2, establishing PINK1/Parkin promote fission and that loss of fission underlies mutant phenotypes.\",\n      \"method\": \"Drosophila genetic epistasis, double-mutant analysis, mitochondrial morphology quantification\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in Drosophila ortholog with multiple allele combinations, 710 citations\",\n      \"pmids\": [\"18230723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Parkin and PINK1 suppress STING-mediated inflammatory signaling: Prkn-/- and Pink1-/- mice develop strong inflammation following exhaustive exercise or mtDNA mutation accumulation; inflammation and dopaminergic neuron loss are rescued by concurrent STING loss, demonstrating PINK1/Parkin-mediated mitophagy restrains innate immunity by limiting cytosolic mtDNA-triggered STING activation.\",\n      \"method\": \"Knockout mouse models (Prkn-/-, Pink1-/-, Prkn-/-;STING-/-, Prkn-/-;mutator mice), cytokine measurements, dopaminergic neuron counts, genetic rescue\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo genetic epistasis with multiple KO combinations and defined molecular pathway, 1057 citations\",\n      \"pmids\": [\"30135585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RABGEF1, an upstream factor of the endosomal Rab GTPase cascade, is recruited to damaged mitochondria via ubiquitin binding downstream of Parkin; RABGEF1 directs RAB5 and RAB7A to damaged mitochondria; RAB7A depletion inhibits ATG9A vesicle assembly and subsequent autophagosome encapsulation of mitochondria, revealing that Parkin-dependent endosomal Rab cycles regulate mitophagy by assembling ATG9A vesicles.\",\n      \"method\": \"siRNA knockdown, co-immunoprecipitation, live-cell imaging, ATG9A vesicle assembly assay in mammalian cells\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, multiple genetic perturbations, mechanistic pathway defined\",\n      \"pmids\": [\"29360040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PINK1 phosphorylation of Miro on S156 promotes Parkin interaction with Miro, Miro ubiquitination and degradation, Parkin recruitment to mitochondria, and Parkin-dependent arrest of axonal mitochondrial transport; phosphomimetic Miro T298E/T299E inhibits PINK1-induced Miro ubiquitination, Parkin recruitment, and mitochondrial arrest.\",\n      \"method\": \"Phosphomimetic and non-phosphorylatable Miro mutants, co-immunoprecipitation, axonal transport imaging in neurons\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — phosphomimetic mutagenesis with functional cellular phenotype (axonal transport), Co-IP\",\n      \"pmids\": [\"27679849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Parkin mediates both mono- and polyubiquitination of VDAC1 in a PINK1-dependent manner; VDAC1 polyubiquitination is required for mitophagy whereas VDAC1 monoubiquitination (K274) suppresses apoptosis by limiting mitochondrial calcium uptake through the MCU channel; a PD patient Parkin mutation T415N loses monoubiquitination but retains polyubiquitination capacity and fails to rescue PD phenotypes in Drosophila.\",\n      \"method\": \"Ubiquitination site mutagenesis, Drosophila transgenic models, mitophagy assays, apoptosis assays, mitochondrial calcium measurements\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis of specific ubiquitination sites with in vivo Drosophila validation and multiple cellular phenotype readouts\",\n      \"pmids\": [\"32047033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Parkin directly binds Bcl-2 via its C terminus and mediates mono-ubiquitination of Bcl-2, increasing Bcl-2 steady-state levels and enhancing Bcl-2/Beclin-1 interaction to inhibit autophagy; overexpression of E3 ligase-deficient Parkin does not affect LC3 conversion, establishing E3 activity is required.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination assay, LC3 conversion assay, Parkin knockdown/overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus in vitro ubiquitination, ligase-dead mutant control, single lab\",\n      \"pmids\": [\"20889974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Parkin interacts with APC/C coactivators Cdc20 and Cdh1 to mediate degradation of key mitotic regulators independently of APC/C; Parkin is phosphorylated and activated by Polo-like kinase 1 (Plk1) during mitosis; Parkin deficiency causes mitotic defects, genomic instability, and overexpression of mitotic substrates.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination assay, kinase assay (Plk1 phosphorylation of Parkin), Parkin knockout cell mitosis assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and in vitro kinase/ubiquitination assays with defined cellular phenotype, single lab\",\n      \"pmids\": [\"26387737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Parkin interacts with pyruvate kinase M2 (PKM2) both in vitro and in vivo; this interaction is increased during glucose starvation; Parkin ubiquitinates PKM2 without affecting its stability but decreases its enzymatic activity, thereby regulating glycolysis.\",\n      \"method\": \"Biochemical purification, co-immunoprecipitation, in vitro ubiquitination assay, PKM2 enzymatic activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro ubiquitination plus enzymatic activity assay plus Co-IP, single lab\",\n      \"pmids\": [\"26975375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Parkin ubiquitinates Mfn2, and Parkin-dependent ubiquitination of Mfn2 regulates ER-mitochondria tethering; Parkin-deficient cells and parkin-mutant human fibroblasts show decreased ER-mitochondria contact; a non-ubiquitinatable Mfn2 mutant fails to restore ER-mitochondria physical and functional interaction; catalytically inactive Parkin has no effect on cytosolic Ca2+ transients.\",\n      \"method\": \"Confocal microscopy (ER-mitochondria contact quantification), Ca2+ flux measurements, Parkin KO mouse fibroblasts, patient fibroblasts, Mfn2 ubiquitination site mutagenesis, Drosophila in vivo locomotion rescue\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cellular and in vivo readouts with mutagenesis, but mainly single lab\",\n      \"pmids\": [\"30219582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Parkin mediates ubiquitination of VPS35 (retromer component) with atypical poly-ubiquitin chains at three C-terminal lysines; this ubiquitination does not promote proteasomal degradation of VPS35 but parkin knockout mice show marked decrease in WASH complex components and selective disruption of ATG9A vesicular sorting, suggesting Parkin modulates retromer-dependent endosomal sorting.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination assay, ubiquitin chain linkage analysis, parkin KO mouse brain fractionation, ATG9A trafficking assay in primary cortical neurons\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and cellular ubiquitination with defined cargo site mapping and KO phenotype, single lab\",\n      \"pmids\": [\"29893854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"USP8 deubiquitinase preferentially removes K6-linked ubiquitin conjugates from Parkin autoubiquitination; USP8 silencing causes persistence of K6-linked Ub conjugates on Parkin, delaying its translocation to damaged mitochondria and completion of mitophagy.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitin linkage analysis, USP8 knockdown, quantitative mitophagy assay\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP with defined linkage analysis and functional mitophagy readout, single lab\",\n      \"pmids\": [\"25700639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"USP33 localizes to the outer mitochondrial membrane, interacts with Parkin, and deubiquitinates Parkin in a DUB activity-dependent manner, preferentially removing K6, K11, K48, and K63-linked ubiquitin conjugates mainly at Lys435; USP33 knockdown increases Parkin protein stability and translocation to depolarized mitochondria, enhancing mitophagy.\",\n      \"method\": \"Co-immunoprecipitation, in vitro deubiquitination assay, ubiquitin linkage-specific analysis, Parkin translocation assay, quantitative mitophagy assay\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro DUB assay plus cellular functional assays with specific site identification, single lab\",\n      \"pmids\": [\"31432739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Deubiquitinating enzymes USP30 and USP35 regulate Parkin-mediated mitophagy; USP30 delays mitophagy by delaying Parkin recruitment to mitochondria; USP35 regulates mitophagy through an alternative mechanism and translocates from mitochondria to cytosol during CCCP-induced mitophagy.\",\n      \"method\": \"Quantitative mitophagy assay, USP overexpression/knockdown, Parkin recruitment assay by live imaging\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional assays with defined mitophagy phenotype but limited mechanistic detail for USP30 action on Parkin\",\n      \"pmids\": [\"25915564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MITOL/MARCH5 ubiquitinates Parkin at lysine 220 to promote its proteasomal degradation; MITOL-mediated Parkin degradation fine-tunes mitophagy by controlling Parkin quantity; MITOL deletion leads to accumulation of phosphorylated active Parkin in the ER, causing FKBP38 degradation and enhanced cell death.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination assay, ubiquitination site mutagenesis (K220), proteasome inhibitor experiments, MITOL deletion cellular assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro ubiquitination with specific site identification and functional consequence, single lab\",\n      \"pmids\": [\"33565245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Parkin and PINK1 are subject to neddylation (NEDD8 conjugation); neddylation of Parkin increases its E3 ligase activity; PD neurotoxin MPP+ inhibits neddylation of both Parkin and PINK1.\",\n      \"method\": \"In vitro neddylation assay, E3 ligase activity assay, Drosophila dAPP-BP1 overexpression epistasis, MPP+ treatment experiments\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro assay plus Drosophila genetic epistasis, single lab\",\n      \"pmids\": [\"22388932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Combined phosphorylation of Parkin by casein kinase I and cyclin-dependent kinase 5 (Cdk5) decreases Parkin solubility, causing its aggregation and inactivation; combined kinase inhibition partially reverses aggregative properties of pathogenic Parkin point mutants; enhanced Parkin phosphorylation is detected in brain areas of sporadic PD patients and correlates with increased p25 (Cdk5 activator) levels.\",\n      \"method\": \"In vitro kinase assay, Parkin solubility/aggregation assay, kinase inhibitor treatment in cells, sporadic PD brain tissue analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro kinase assay plus cellular and postmortem tissue validation, single lab\",\n      \"pmids\": [\"19050041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PHB2 stabilizes PINK1 on mitochondria via the PARL-PGAM5-PINK1 axis; PHB2 depletion destabilizes PINK1, blocking PRKN/Parkin recruitment to mitochondria; PHB2 overexpression directly induces Parkin recruitment; PHB2-mediated mitophagy is dependent on the inner membrane protease PARL and on PGAM5 processing by PARL.\",\n      \"method\": \"PHB2 knockdown/overexpression, PINK1 stability assay, Parkin translocation assay, PARL and PGAM5 genetic manipulation in mouse embryo fibroblasts\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional pathway placement with multiple genetic perturbations but no in vitro reconstitution, single lab\",\n      \"pmids\": [\"31177901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Miro1 interacts with a small pool of Parkin before mitochondrial damage in a PINK1-independent and ubiquitination-independent manner, serving as a calcium-sensitive docking site for Parkin on mitochondria; knockdown of Miro proteins reduces Parkin translocation to mitochondria and suppresses mitophagy; Miro1 EF-hand domains control Miro1 ubiquitination and Parkin recruitment.\",\n      \"method\": \"Co-immunoprecipitation, Miro knockdown, live-cell Parkin translocation assay, EF-hand domain mutagenesis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP plus functional knockdown with defined phenotype, but partial mechanistic follow-up on EF-hand domains\",\n      \"pmids\": [\"30504269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Parkin functions as a RING-type E3 ubiquitin-protein ligase collaborating with E2 ubiquitin-conjugating enzymes UbcH7 and UbcH8; loss of this E3 ligase activity is the molecular basis of autosomal recessive juvenile parkinsonism.\",\n      \"method\": \"In vitro ubiquitin ligase assay, E2 enzyme specificity assay, pathogenic mutation functional analysis\",\n      \"journal\": \"Journal of molecular medicine (Berlin, Germany)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro E3 ligase reconstitution, foundational characterization widely replicated\",\n      \"pmids\": [\"11692161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Parkin promotes DNA repair: parkin-deficient cells show reduced DNA excision repair restored by wild-type but not pathological mutant Parkin; Parkin interacts with PCNA (proliferating cell nuclear antigen), a coordinator of DNA excision repair; Parkin protects against DNA damage-induced cell death.\",\n      \"method\": \"DNA repair assay in parkin-deficient cells, transfection rescue with WT vs. mutant Parkin, co-immunoprecipitation with PCNA, cell death assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single Co-IP, limited mechanistic follow-up\",\n      \"pmids\": [\"19285961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PARK2 physically interacts with β-catenin and EGFR and promotes their ubiquitination in an E3 ligase activity-dependent manner, downregulating Wnt- and EGF-stimulated pathways and inhibiting glioma cell growth.\",\n      \"method\": \"Co-immunoprecipitation, in vitro/cellular ubiquitination assay, PARK2 overexpression/knockdown in glioma cells, in vivo xenograft\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus ubiquitination assay with ligase-dead control and functional readout, single lab\",\n      \"pmids\": [\"25877876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PARK2 directly binds to and ubiquitinates BCL-XL; PARK2 inactivation leads to aberrant accumulation of BCL-XL in vitro and in vivo; cancer-specific PARK2 mutations abrogate ubiquitination of BCL-XL; PARK2 modulates mitochondrial depolarization and apoptosis in a BCL-XL-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ubiquitination assay, PARK2 KO mouse tissue, functional apoptosis assay\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus in vitro ubiquitination plus in vivo KO, functional rescue, single lab\",\n      \"pmids\": [\"28038320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In Drosophila, PINK1-mediated phosphorylation of Parkin at Ser94 (equivalent to human Ser65) boosts Parkin ubiquitin-ligase activity; phosphomimetic Parkin accelerates mitochondrial fragmentation/aggregation and mitochondrial protein degradation independently of PINK1 activity; non-phosphorylatable Parkin cannot rescue PINK1-null muscle phenotype fully; Parkin phosphorylation affects dopamine release and dopaminergic neuron survival in vivo.\",\n      \"method\": \"Drosophila transgenic models expressing phosphomimetic and non-phosphorylatable Parkin, mitochondrial morphology assay, dopamine release measurement, dopaminergic neuron survival quantification\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo Drosophila ortholog study with phosphomimetic mutagenesis and multiple functional readouts\",\n      \"pmids\": [\"24901221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRKN/Parkin ubiquitinates PA2G4/EBP1 at lysine 376 on damaged mitochondria; ubiquitinated PA2G4/EBP1 interacts with autophagy receptor SQSTM1/p62 to induce mitophagy; neuron-specific Pa2g4 knockout impairs mitophagy and worsens ischemia-reperfusion neuronal death.\",\n      \"method\": \"Ubiquitination site mutagenesis, co-immunoprecipitation, neuron-specific knockout mouse, ischemia-reperfusion model, AAV rescue\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — specific ubiquitination site identified with in vivo KO and functional rescue, single lab\",\n      \"pmids\": [\"37712850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Under hypoxia, GPCPD1 (depalmitoylated by LYPLA1) relocates to the outer mitochondrial membrane and binds VDAC1, disrupting VDAC1 oligomerization; increased VDAC1 monomer provides more sites for PRKN-mediated polyubiquitination, triggering mitophagy.\",\n      \"method\": \"Co-immunoprecipitation, VDAC1 oligomerization assay, PRKN ubiquitination assay, GPCPD1 depalmitoylation assay, mitophagy quantification\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP based mechanism with limited in vitro reconstitution, single lab\",\n      \"pmids\": [\"36803235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Massively parallel variant abundance by sequencing (VAMP-seq) of 9219 Parkin variants in human cells shows most low-abundance variants are proteasome targets located in structured domains; a degron region proximal to the activation element (ACT) is mapped; missense variants cause degradation either by destabilizing the native protein or by introducing local degradation signals.\",\n      \"method\": \"VAMP-seq (variant abundance by massively parallel sequencing), proteasome inhibitor experiments, structural mapping of degrons\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genome-scale functional assay with mechanistic structural interpretation, comprehensive coverage\",\n      \"pmids\": [\"38378758\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRKN encodes Parkin, an RBR-type E3 ubiquitin ligase that is normally autoinhibited; upon mitochondrial damage, PINK1 accumulates on the outer mitochondrial membrane and phosphorylates both ubiquitin (Ser65) and the Parkin Ubl domain (Ser65), causing phospho-ubiquitin to bind Parkin's RING1 domain and trigger sequential domain rearrangements (Ubl release → RING2 release) that open the active site; activated Parkin then ubiquitinates multiple outer mitochondrial membrane proteins (including Mfn1/2, VDAC1, Miro, and others), building phospho-ubiquitin chains that serve as the receptor for Parkin itself (feed-forward amplification) and recruit autophagy receptors (OPTN, NDP52) and ATG9A vesicles to initiate autophagosome formation around damaged mitochondria, thereby driving their lysosomal degradation (mitophagy) and preventing cytosolic mtDNA release and STING-dependent innate immune activation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PRKN encodes Parkin, an RBR-type E3 ubiquitin-protein ligase that is the principal effector of PINK1-directed mitophagy and a cause of autosomal recessive juvenile parkinsonism when mutationally inactivated [PMID:11692161, PMID:19029340]. Parkin is normally autoinhibited in the cytosol; upon mitochondrial depolarization, PINK1 accumulates on the outer mitochondrial membrane and phosphorylates ubiquitin at Ser65, which binds a conserved pocket in Parkin's RING1 domain, displacing the Ubl domain and triggering sequential release of the catalytic RING2 domain to expose the active-site cysteine [PMID:24784582, PMID:26161729, PMID:29995846]. Activated Parkin ubiquitinates outer mitochondrial membrane substrates including Mfn2, VDAC1, and Miro, building phospho-ubiquitin chains that recruit additional Parkin (feed-forward amplification) and autophagy adaptors to drive autophagosome assembly around damaged mitochondria; failure of this pathway leads to cytosolic mtDNA release and STING-dependent neuroinflammation, linking Parkin loss to dopaminergic neurodegeneration [PMID:25847540, PMID:32047033, PMID:27679849, PMID:30135585]. Beyond mitophagy, Parkin ubiquitinates diverse substrates including BCL-XL, β-catenin, EGFR, and PKM2, contributing to apoptosis regulation, cell-cycle control, and metabolic homeostasis [PMID:28038320, PMID:25877876, PMID:26975375].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that Parkin is an E3 ubiquitin-protein ligase—and that loss of this activity underlies autosomal recessive juvenile parkinsonism—converted a genetically mapped disease locus into a defined enzymatic function.\",\n      \"evidence\": \"In vitro ubiquitin ligase reconstitution with E2 specificity profiling and pathogenic mutation analysis\",\n      \"pmids\": [\"11692161\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrates unknown\", \"Mechanism of autoinhibition not yet defined\", \"No structural information\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that Parkin selectively translocates to depolarized mitochondria and promotes their autophagic clearance established mitophagy as Parkin's central cellular function, while genetic epistasis in Drosophila placed PINK1/Parkin upstream of mitochondrial fission/fusion dynamics.\",\n      \"evidence\": \"Live-cell imaging and membrane-potential assays in mammalian cells; Drosophila double-mutant analysis with drp1, Opa1, Mfn2\",\n      \"pmids\": [\"19029340\", \"18230723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signal triggering Parkin recruitment unknown\", \"Mechanism linking Parkin to fission machinery unclear\", \"Identity of mitochondrial ubiquitin substrates not yet determined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrating that PINK1 accumulation on damaged mitochondria is both necessary and sufficient for Parkin recruitment established the PINK1→Parkin epistatic axis and explained how mitochondrial damage is sensed.\",\n      \"evidence\": \"Genetic epistasis with PINK1 overexpression/knockdown, disease mutations, and mitophagy assays in mammalian cells\",\n      \"pmids\": [\"20126261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical mechanism of PINK1-mediated Parkin activation (phosphorylation target) unknown\", \"Whether PINK1 directly phosphorylates Parkin or acts indirectly unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of Ser65-phosphorylated ubiquitin as a PINK1 product and allosteric Parkin activator revealed the dual-key activation mechanism (phospho-Ubl + phospho-ubiquitin) and explained how Parkin's latent E3 activity is unleashed on mitochondria.\",\n      \"evidence\": \"In vitro kinase assays, phosphopeptide mass spectrometry, ubiquitin-discharge assays with recombinant proteins; Drosophila phosphomimetic Parkin in vivo\",\n      \"pmids\": [\"24784582\", \"24901221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for phospho-ubiquitin binding to Parkin undetermined\", \"Full domain rearrangement upon activation not yet visualized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Crystal structures of Parkin–phospho-ubiquitin complexes, combined with the demonstration that phospho-ubiquitin chains serve as the mitochondrial Parkin receptor, defined the feed-forward amplification loop: Parkin builds ubiquitin chains → PINK1 phosphorylates them → phospho-Ub chains recruit more Parkin.\",\n      \"evidence\": \"X-ray crystallography (Pediculus Parkin–pUb complex), SAXS, cellular ubiquitin-replacement system, in vitro reconstitution with phosphomimetic tetra-ubiquitin\",\n      \"pmids\": [\"26161729\", \"25847540\", \"26254305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of fully activated human Parkin not yet solved\", \"Catalytic RING2 domain release not structurally visualized\", \"Relative contributions of different OMM substrates to amplification loop unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"High-resolution structures of phosphorylated human Parkin and insect Parkin–E2 complexes revealed the complete two-step activation mechanism: phospho-Ubl rebinds to UPD via a disease-mutation-lined pocket, releasing RING2 and the ACT linker, exposing the catalytic cysteine.\",\n      \"evidence\": \"1.8 Å crystal structure of phosphorylated human Parkin, HDX-MS, NMR of activation intermediates, crystal structure of phosphorylated Bactrocera Parkin–pUb–E2 complex\",\n      \"pmids\": [\"29995846\", \"29967542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of Parkin engaged with a mitochondrial substrate\", \"Dynamics of membrane-proximal activation not captured\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of deubiquitinases USP8, USP30, and USP35 as regulators that oppose Parkin autoubiquitination and substrate ubiquitination established that mitophagy is tuned by an antagonistic DUB network, not solely by PINK1-Parkin activation.\",\n      \"evidence\": \"Ubiquitin-linkage analysis, USP knockdown/overexpression, quantitative mitophagy assays\",\n      \"pmids\": [\"25700639\", \"25915564\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative physiological importance of each DUB in neurons undetermined\", \"Structural basis for K6-linkage selectivity of USP8 on Parkin unknown\", \"In vivo validation in mammalian models lacking\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstration that Parkin-dependent ubiquitination of Miro arrests axonal mitochondrial transport and that RABGEF1 recruitment to ubiquitinated mitochondria activates endosomal Rab cascades for ATG9A vesicle assembly connected Parkin's E3 activity to both mitochondrial motility arrest and autophagosome nucleation.\",\n      \"evidence\": \"Phosphomimetic Miro mutagenesis with axonal transport imaging; siRNA of RABGEF1/RAB7A with ATG9A vesicle assembly assays\",\n      \"pmids\": [\"27679849\", \"29360040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Miro phosphorylation by PINK1 is the obligate trigger for Parkin-Miro interaction in all cell types is unclear\", \"How ATG9A vesicles transition to LC3-positive autophagosomes at the mitochondrial surface not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linking PINK1/Parkin-mediated mitophagy to suppression of STING-dependent innate immunity provided a direct pathogenic mechanism for neurodegeneration: in the absence of Parkin, cytosolic mtDNA accumulates and triggers neuroinflammation, which is rescued by STING deletion.\",\n      \"evidence\": \"Prkn−/−, Pink1−/−, and Prkn−/−;STING−/− knockout mice with exhaustive exercise and mutator backgrounds; cytokine measurements, dopaminergic neuron counts\",\n      \"pmids\": [\"30135585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STING-mediated inflammation is the primary driver of dopaminergic neuron loss in human PD is not established\", \"Contribution of other innate immune sensors (cGAS, TLR9) to Parkin-loss phenotypes not delineated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Dissection of VDAC1 mono- versus polyubiquitination by Parkin separated mitophagy (polyubiquitination-dependent) from anti-apoptotic signaling (monoubiquitination at K274 suppresses MCU-mediated Ca²⁺ uptake), revealing that Parkin has ubiquitin-chain-type-specific, functionally distinct outputs on a single substrate.\",\n      \"evidence\": \"Ubiquitination site mutagenesis, mitophagy and apoptosis assays, mitochondrial calcium measurements, Drosophila transgenic rescue with PD-patient Parkin T415N mutant\",\n      \"pmids\": [\"32047033\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this mono/polyUb distinction applies to other Parkin substrates untested\", \"E2 enzyme(s) specifying chain type on VDAC1 not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Massively parallel functional profiling of ~9,200 Parkin variants mapped a degron near the ACT element and showed that most pathogenic missense variants cause protein instability and proteasomal degradation, unifying the genotype-phenotype landscape.\",\n      \"evidence\": \"VAMP-seq in human cells with proteasome inhibitor rescue and structural degron mapping\",\n      \"pmids\": [\"38378758\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Variant effects on enzymatic activity and mitophagy not measured in parallel\", \"Whether degradation-prone variants can be pharmacologically stabilized in neurons is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for Parkin engagement with mitochondrial-membrane-embedded substrates, the relative contribution of individual substrates to mitophagy versus non-mitophagy functions in dopaminergic neurons, and whether pharmacological Parkin activation can be achieved therapeutically.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of membrane-engaged Parkin ubiquitinating a substrate\", \"Substrate hierarchy on damaged mitochondria not systematically defined in neurons\", \"No pharmacological Parkin activator validated in vivo\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 4, 6, 12, 26, 28, 29, 31]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [2, 26, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 6, 10, 11, 12]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [0, 1, 6, 10, 12, 31]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 26, 33]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [12, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [0, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PINK1\",\n      \"VDAC1\",\n      \"MFN2\",\n      \"RHOT1\",\n      \"RHOT2\",\n      \"VPS35\",\n      \"USP30\",\n      \"USP33\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}